不同剂量瑞舒伐他汀钙对经皮冠状动脉介入治疗术后预后的影响

Effects of different doses of atorvastatin calcium on the prognosis of patients with percutaneous coronary intervention

目的：对比观察不同剂量瑞舒伐他汀钙在冠心病PCI术后患者中长期应用的疗效比较。方法选择2010年10月至2012年6月在平顶山市第二人民医院行PCI介入治疗的200例患者，随机分别给予瑞舒伐他汀钙片10、20 mg/d，长期口服，随访1年，出院后1、3、6、12个月复查血脂，血糖，肝肾功能，心肌酶，CRP，及出院后心绞痛发作次数，心肌梗死发生率，死亡率，以评价不同剂量的瑞舒伐他汀钙片对PCI术后患者预后的影响。结果1年MACE发生率低剂量治疗组为14.15%，强化治疗组为10.1%，两组间比较差异有统计学意义（P〈0.05）。血脂达标率常规治疗组为64.2%，强化治疗组为78.4%，差异有统计学意义（P〈0.05）。两组的肝功能异常及肌病发生率低剂量治疗组为3.7%，强化治疗组为2.2%，差异无统计学意义（P〉0.05）。结论 PCI术后患者长期口服10、20 mg/d的瑞舒伐他汀治疗安全有效，长期口服高剂量的瑞舒伐他汀钙对减少患MACE的发生率有明显差别；不同剂量的瑞舒伐他汀钙肝功能异常及肌病发生率无明显差异。

ObjectiveTo compare the at comparative observation on the therapeutic effect of different doses of rosuvastatin calcium in long-term application of PCI in the postoperative patients with coronary heart disease.Method For postoperative PCI patients,randomly treated Rosuvastatin Calcium Tablets 10mg,20mg,long-term oral,follow-up of 1 year,1,3,6,12 months after discharge of blood lipid,blood glucose,liver and kidney function,myocardial enzyme,CRP,and after discharge frequency of angina,myocardial infarction incidence,the mortality rate,to evaluate the different doses of Rosuvastatin Calcium Tablets effect on the prognosis of patients after PCI operation.Results 1 years at MACE incidence of low dosage treatment group was 14.15%,10.1% in the intensive therapy group,two of the difference between groups was statistically significant atP〈0.05,at lipid goal attainment;conventional treatment group was 64.2%,78.4% in the intensive therapy group,P〈0.05,two group there were significant differences between the. Liver function abnormalities and two groups occurred at the rate of 3.7% myopathy as low dosage treatment group,and 2.2% in the intensive therapy group,P〉0.05,between the two groups had no significant differences between.Conclusion PCI on postoperative patients with long-term oral at 20mg/at day,10mg/at days rosuvastatin calcium and effective long-term statin therapy,oral administration of high doses of rosuvastatin calcium reduces the risk of at MACE on the incidence of significantly different at different doses;rosuvastatin calcium abnormal liver function and there is no difference between myopathy.